Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

380
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
380
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

454
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
454
Drug Therapy01:28

Drug Therapy

97
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
97

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Apathy in Parkinson's Disease: Distinguishing Overlapping Symptoms Via Network Analysis.

Movement disorders clinical practice·2026
Same author

True vignettes: interesting, illustrative examples of behavioral abnormalities in people with Parkinson's disease.

Arquivos de neuro-psiquiatria·2026
Same author

Cognitive Fluctuations, Neuropsychiatric Burden, and Quality of Life in Moderate-Advanced Dementia With Lewy Bodies: The Role of Dysautonomia.

Neurology·2026
Same author

Perspective: Depression in Persons with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs.

Movement disorders clinical practice·2025

関連する実験動画

Updated: Sep 10, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.5K

パーキンソン病に特化した 精神疾患の治療薬が必要でしょうか?

Kelly A Mills1, Gregory M Pontone2,3

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Journal of Parkinson's disease
|August 21, 2025
PubMed
まとめ

パーキンソン病 (PD) の患者の精神症状に対する新しい薬の開発には,治療目標へのさらなる注意が必要です. このレビューでは,現在の薬理学的治療法を検討し,改善された治療法の将来の方向性を提案しています.

キーワード:
パーキンソン病心配する無関心うつ病インパルス制御精神障害

さらに関連する動画

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

関連する実験動画

Last Updated: Sep 10, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.5K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

科学分野:

  • 神経科学
  • 精神科
  • 薬理学について

背景:

  • 精神症状はパーキンソン病 (PWP) の患者に多く見られ,しばしば前兆期に現れる.
  • これらの症状は,運動障害とその治療法と密接に関連しており, 潜在的メカニズム的なつながりを示唆しています.

研究 の 目的:

  • PWPにおける精神症状に対する既存の薬理学的治療法を検討する.
  • 精神疾患の症状に対する新しい薬の開発のための将来の戦略と目標を模索する.

主な方法:

  • 薬理学的治療のための現在の証拠の文献レビュー.
  • 精神症状と運動症状の間の潜在的メカニズム的なリンクの探索.

主要な成果:

  • PWPにおける精神症状の現在の薬理学的治療法について論じています.
  • 精神症状,運動症状,治療の複雑な相互作用が強調されています.

結論:

  • 機械的な関連性に関するさらなる研究が必要である.
  • 新しい治療目標とアプローチは パーキンソン病の精神症状に対する効果的な薬の開発に不可欠です